Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab adjunctive therapy with topical corticosteroids for moderate to severe atopic dermatitis
2014-000049-56Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Lebrikizumab + topical corticosteroids with Placebo + topical corticosteroids (2 arms). Primary endpoint: Percentage of patients achieving EASI-50 at Week 12. Started Mar 2015; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2014-000049-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000049-56.